Increase in serum creatinine levels after PARP inhibitor treatment

Increase in serum creatinine levels after PARP inhibitor treatment

Bibliographic Details
Main Authors:	Di You, Lan Zhong, Rutie Yin, Liang Song
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Series:	Journal of Obstetrics and Gynaecology
Subjects:	ovarian cancer parp inhibitors creatinine renal function olaparib gynaecological oncology
Online Access:	http://dx.doi.org/10.1080/01443615.2023.2171781

Similar Items

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

Use of First-Line PARP Inhibitors in Ovarian Cancer
by: Ursula Hasler-Strub
Published: (2020-11-01)

Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials
by: Guojuan Sun, et al.
Published: (2024-09-01)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
by: Yifan Jiang, et al.
Published: (2020-07-01)

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials
by: Alecu I, et al.
Published: (2018-02-01)

What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China
by: Depu Zhang, et al.
Published: (2022-08-01)

Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis
by: Xiu Chen, et al.
Published: (2023-01-01)

Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
by: Yan Wei, et al.
Published: (2024-03-01)

Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01)

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
by: Kamila Burdova, et al.
Published: (2019-10-01)

Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors
by: Cheng-Zhi Gao, et al.
Published: (2019-01-01)

Case report of two long term ovarian cancer survivors with brain metastases following multimodal treatment including chemotherapy, radiotherapy and maintenance olaparib: An institutional case series and literature review
by: Yukari Tsuchino, et al.
Published: (2024-08-01)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
by: Natalya Maluchenko, et al.
Published: (2022-10-01)

HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells
by: Sabine Hombach‐Klonisch, et al.
Published: (2019-02-01)

Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma
by: Chung Ying Chan, et al.
Published: (2022-10-01)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
by: Hongyu Qin, et al.
Published: (2023-01-01)

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
by: R. de Haan, et al.
Published: (2019-09-01)

Real‐world data of poly (ADP‐ribose) polymerase inhibitor response in Japanese patients with ovarian cancer
by: Ryosuke Uekusa, et al.
Published: (2024-04-01)

Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
by: Chuanlin Wang, et al.
Published: (2022-12-01)

PARP Inhibitors in the Treatment of Ovarian Cancer
by: Andrzej Paweł Zuzak, et al.
Published: (2025-02-01)

PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE
by: S. V. KHOKHLOVA, et al.
Published: (2017-06-01)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
by: Angela Dalia Ricci, et al.
Published: (2020-08-01)

The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors
by: А. А. Gritskevich, et al.
Published: (2021-06-01)

Advances in the use of PARP inhibitor therapy for breast cancer
by: Kelly E McCann, et al.
Published: (2018-08-01)

Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale
by: Andreas Hallqvist, et al.
Published: (2021-10-01)

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer – International considerations amongst upper middle- and high-income countries (UMIC and HIC)
by: Jeffrey C.H. Goh, et al.
Published: (2022-08-01)

The PARP Inhibitor Olaparib Modulates the Transcriptional Regulatory Networks of Long Non-Coding RNAs during Vasculogenic Mimicry
by: Mónica Fernández-Cortés, et al.
Published: (2020-12-01)

Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
by: Fen Xiao, et al.
Published: (2024-08-01)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
by: Ymera Pignochino, et al.
Published: (2017-04-01)

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
by: Giovanni Canil, et al.
Published: (2023-05-01)

Never tear us a-PARP: Dealing with DNA lesions during mitosis
by: Pepijn M. Schoonen, et al.
Published: (2018-01-01)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
by: Angiolo Gadducci, et al.
Published: (2019-01-01)

Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis
by: Brigida Anna Maiorano, et al.
Published: (2025-02-01)

Tertiary Prevention of Ovarian Cancer After PARP Inhibitor Therapy
by: ZANG Rongyu
Published: (2023-02-01)

Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
by: Sudeep Gupta, et al.
Published: (2019-11-01)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
by: Mary-Ann Xavier, et al.
Published: (2021-08-01)

Olaparib Conjugates with Selenopheno[3,2-<i>c</i>]quinolinone Inhibit PARP1 and Reverse ABCB1-Related Multidrug Resistance
by: Marina Makrecka-Kuka, et al.
Published: (2022-11-01)

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin
by: Bahram Sharif-Askari, et al.
Published: (2023-03-01)

Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress
by: Sidneia Sousa Santos, et al.
Published: (2022-06-01)

A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China
by: Jinghong Chen, et al.
Published: (2024-01-01)